Nathan Weinstein
Stock Analyst at Aegis Capital
(0.28)
# 4,484
Out of 5,237 analysts
56
Total ratings
13.79%
Success rate
-24.81%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $0.78 | +10,197.34% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $400 → $300 | $7.98 | +3,659.40% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $180 → $120 | $2.05 | +5,753.66% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $400 → $350 | $12.00 | +2,816.67% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $1.88 | +219.15% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $4.62 | +549.35% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $14.88 | -32.80% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $16.46 | +197.69% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $63,000 → $1,800 | $2.81 | +63,956.94% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $4.96 | +43,448.39% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $1.83 | +6,457.38% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.41 | +2,358.81% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $41.55 | +34.78% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $4.04 | +568.32% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.82 | +4,147.06% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.17 | +925.64% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $24.13 | +210.82% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $2.28 | +3,759.65% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $0.67 | +26,622.09% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $8.45 | +65.68% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $15.02 | +1,364.71% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $3.03 | +180.53% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $0.78
Upside: +10,197.34%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400 → $300
Current: $7.98
Upside: +3,659.40%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $180 → $120
Current: $2.05
Upside: +5,753.66%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $400 → $350
Current: $12.00
Upside: +2,816.67%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $1.88
Upside: +219.15%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $4.62
Upside: +549.35%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $14.88
Upside: -32.80%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $16.46
Upside: +197.69%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000 → $1,800
Current: $2.81
Upside: +63,956.94%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $4.96
Upside: +43,448.39%
Dec 7, 2021
Initiates: Buy
Price Target: $120
Current: $1.83
Upside: +6,457.38%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.41
Upside: +2,358.81%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $41.55
Upside: +34.78%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $4.04
Upside: +568.32%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.82
Upside: +4,147.06%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $1.17
Upside: +925.64%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $24.13
Upside: +210.82%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $2.28
Upside: +3,759.65%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $0.67
Upside: +26,622.09%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $8.45
Upside: +65.68%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $15.02
Upside: +1,364.71%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $3.03
Upside: +180.53%